Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,576,852
  • Shares Outstanding, K 146,662
  • Annual Sales, $ 0 K
  • Annual Income, $ -422,770 K
  • EBIT $ -548 M
  • EBITDA $ -575 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.10

Options Overview Details

View History
  • Implied Volatility 78.07% (+16.18%)
  • Historical Volatility 68.13%
  • IV Percentile 24%
  • IV Rank 29.12%
  • IV High 155.38% on 11/13/25
  • IV Low 46.31% on 01/21/25
  • Expected Move (DTE 8) 2.18 (12.58%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 109
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 2,637
  • Open Int (30-Day) 2,206
  • Expected Range 15.19 to 19.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.76
  • Number of Estimates 12
  • High Estimate -0.62
  • Low Estimate -0.93
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -13.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.66 +4.26%
on 11/13/25
20.61 -15.72%
on 12/05/25
-0.21 (-1.19%)
since 11/11/25
3-Month
12.58 +38.08%
on 09/22/25
20.61 -15.72%
on 12/05/25
+2.55 (+17.21%)
since 09/11/25
52-Week
10.57 +64.33%
on 04/07/25
24.34 -28.65%
on 02/05/25
-6.50 (-27.23%)
since 12/11/24

Most Recent Stories

More News
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common...

DNLI : 17.37 (-1.14%)
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and,...

DNLI : 17.37 (-1.14%)
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty...

RPRX : 38.81 (+1.44%)
DNLI : 17.37 (-1.14%)
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty...

RPRX : 38.81 (+1.44%)
DNLI : 17.37 (-1.14%)
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed,...

DNLI : 17.37 (-1.14%)
Denali Therapeutics Announces Board and Executive Leadership Updates

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren...

DNLI : 17.37 (-1.14%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.5900 (+3.92%)
AVAI : 0.3151 (-6.50%)
DNLI : 17.37 (-1.14%)
EDIT : 2.56 (-1.54%)
XNCR : 17.06 (-0.58%)
Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Denali Therapeutics, with a price target of $35.00. The company’s shares closed yesterday at $14.98.Elevate Your Investing...

DNLI : 17.37 (-1.14%)
Wedbush Keeps Their Buy Rating on Denali Therapeutics (DNLI)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Denali Therapeutics, with a price target of $30.00. The company’s shares closed yesterday at $14.98.Elevate Your Investing...

DNLI : 17.37 (-1.14%)
Denali Therapeutics Faces FDA Review Extension

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Denali Therapeutics...

DNLI : 17.37 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 18.25
2nd Resistance Point 18.01
1st Resistance Point 17.69
Last Price 17.37
1st Support Level 17.12
2nd Support Level 16.88
3rd Support Level 16.56

See More

52-Week High 24.34
Fibonacci 61.8% 19.08
Fibonacci 50% 17.46
Last Price 17.37
Fibonacci 38.2% 15.83
52-Week Low 10.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar